BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 17614272)

  • 1. Does HPV-status 6-12 months after treatment of high grade dysplasia in the uterine cervix predict long term recurrence?
    Strander B; Ryd W; Wallin KL; Wärleby B; Zheng B; Milsom I; Gharizadeh B; Pourmand N; Andersson-Ellström A
    Eur J Cancer; 2007 Aug; 43(12):1849-55. PubMed ID: 17614272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of recurrence after treatment for high-grade cervical intraepithelial neoplasia: the role of human papillomavirus testing and age at conisation.
    Verguts J; Bronselaer B; Donders G; Arbyn M; Van Eldere J; Drijkoningen M; Poppe W
    BJOG; 2006 Nov; 113(11):1303-7. PubMed ID: 16978225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistent human papillomavirus infection and smoking increase risk of failure of treatment of cervical intraepithelial neoplasia (CIN).
    Acladious NN; Sutton C; Mandal D; Hopkins R; Zaklama M; Kitchener H
    Int J Cancer; 2002 Mar; 98(3):435-9. PubMed ID: 11920596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical performance of hybrid capture 2 human papillomavirus testing for recurrent high-grade cervical/vaginal intraepithelial neoplasm in patients with an ASC-US Papanicolaou test result during long-term posttherapy follow-up monitoring.
    De Vivar AD; Dawlett M; Wang JP; Jack A; Gong Y; Staerkel G; Guo M
    Arch Pathol Lab Med; 2015 Feb; 139(2):219-24. PubMed ID: 25611104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HPV testing can reduce the number of follow-up visits in women treated for cervical intraepithelial neoplasia grade 3.
    Zielinski GD; Rozendaal L; Voorhorst FJ; Berkhof J; Snijders PJ; Risse EJ; Runsink AP; de Schipper FA; Meijer CJ
    Gynecol Oncol; 2003 Oct; 91(1):67-73. PubMed ID: 14529664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study.
    Kocken M; Helmerhorst TJ; Berkhof J; Louwers JA; Nobbenhuis MA; Bais AG; Hogewoning CJ; Zaal A; Verheijen RH; Snijders PJ; Meijer CJ
    Lancet Oncol; 2011 May; 12(5):441-50. PubMed ID: 21530398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human papillomavirus-based cervical cancer prevention: long-term results of a randomized screening trial.
    Denny L; Kuhn L; Hu CC; Tsai WY; Wright TC
    J Natl Cancer Inst; 2010 Oct; 102(20):1557-67. PubMed ID: 20884893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human papilloma virus testing in patient follow-up post cone biopsy due to high-grade cervical intraepithelial neoplasia.
    Almog B; Gamzu R; Kuperminc MJ; Levin I; Fainaru O; Niv J; Bar-Am A
    Gynecol Oncol; 2003 Mar; 88(3):345-50. PubMed ID: 12648585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type-specific HPV geno-typing improves detection of recurrent high-grade cervical neoplasia after conisation.
    Heymans J; Benoy IH; Poppe W; Depuydt CE
    Int J Cancer; 2011 Aug; 129(4):903-9. PubMed ID: 21064091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study.
    Dalstein V; Riethmuller D; Prétet JL; Le Bail Carval K; Sautière JL; Carbillet JP; Kantelip B; Schaal JP; Mougin C
    Int J Cancer; 2003 Sep; 106(3):396-403. PubMed ID: 12845680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence.
    Kjær SK; Frederiksen K; Munk C; Iftner T
    J Natl Cancer Inst; 2010 Oct; 102(19):1478-88. PubMed ID: 20841605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of high-grade cervical intraepithelial neoplasia in cytologically normal women by human papillomavirus testing.
    Carozzi F; Ronco G; Confortini M; Noferini D; Maddau C; Ciatto S; Segnan N
    Br J Cancer; 2000 Dec; 83(11):1462-7. PubMed ID: 11076654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is therapeutic conization sufficient to eliminate a high-risk HPV infection of the uterine cervix? A clinicopathological analysis.
    Bodner K; Bodner-Adler B; Wierrani F; Kimberger O; Denk C; Grünberger W
    Anticancer Res; 2002; 22(6B):3733-6. PubMed ID: 12552985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Follow-up by combined cytology and human papillomavirus testing for patients post-cone biopsy: results of a long-term follow-up.
    Bar-Am A; Gamzu R; Levin I; Fainaru O; Niv J; Almog B
    Gynecol Oncol; 2003 Oct; 91(1):149-53. PubMed ID: 14529675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-risk HPV testing in women with borderline and mild dyskaryosis: long-term follow-up data and clinical relevance.
    Denise Zielinski G; Snijders PJ; Rozendaal L; Voorhorst FJ; Runsink AP; de Schipper FA; Meijer CJ
    J Pathol; 2001 Oct; 195(3):300-6. PubMed ID: 11673826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer.
    Wright TC; Denny L; Kuhn L; Pollack A; Lorincz A
    JAMA; 2000 Jan; 283(1):81-6. PubMed ID: 10632284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence of human papillomavirus infection after therapeutic conization for CIN 3: is it an alarm for disease recurrence?
    Nagai Y; Maehama T; Asato T; Kanazawa K
    Gynecol Oncol; 2000 Nov; 79(2):294-9. PubMed ID: 11063660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant promoter methylation can be useful as a marker of recurrent disease in patients with cervical intraepithelial neoplasia grade III.
    Terra AP; Murta EF; Maluf PJ; Caballero OL; Brait M; Adad SJ
    Tumori; 2007; 93(6):572-9. PubMed ID: 18338492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears.
    Rozendaal L; Walboomers JM; van der Linden JC; Voorhorst FJ; Kenemans P; Helmerhorst TJ; van Ballegooijen M; Meijer CJ
    Int J Cancer; 1996 Dec; 68(6):766-9. PubMed ID: 8980181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of HPV DNA HR assay in females as a marker of recurrent disease following treatment of cervical intraepithelial neoplasia.
    Mikolajczyk K; Kedzia W; Zaba R; Silny W
    Ginekol Pol; 2011 Sep; 82(9):670-4. PubMed ID: 22379926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.